SCHEMBL2647241

SCHEMBL2647241

O=C(O)CCNC(=O)c1ccc(C(=O)/C(=C\C(=O)C2=COC=C(C3=CC=CC(F)(F)C3(F)F)O2)c2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCGR P47871 19/20 0.38
GIPR P48546 3/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2C9 P11712 1/20 0.36
KCNH2 Q12809 1/20 0.36
ADCY6 O43306 1/20 0.35
ADCY3 O60266 1/20 0.35
ADCY9 O60503 1/20 0.35
ADCY5 O95622 1/20 0.35
ADCY8 P40145 1/20 0.35
ADCY7 P51828 1/20 0.35
ADCY2 Q08462 1/20 0.35
ADCY1 Q08828 1/20 0.35
ADCY4 Q8NFM4 1/20 0.35
GLP1R P43220 1/20 0.35
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6913807 0.89 GCG (0.34) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL6914041 0.84 GCGR (0.36) GCGRGIPR
SCHEMBL2647920 0.77 GCGR (0.53) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2647916 0.77 GCGR (0.53) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2647844 0.74 TRPV1 (0.51) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2647843 0.74 TRPV1 (0.51) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2648042 0.74 GCGR (0.53) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2648152 0.74 GCGR (0.53) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2648150 0.74 GCGR (0.53) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2655666 0.73 GCGR (0.49) GCGRGIPRCYP3A4CYP2C8CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463715-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-10-06 EP disclosed
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR GCGR 4/4885GIPR 3/4885CYP3A4 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.